Riskpilot← Back to searchSign inGet full accessSIRIS BIOFOTONTERAPI AS
ASActiveOrg 911943212Galterudbekken 55B, 2614 LillehammerOther human health activities n.e.c. · NACE 8699Est. 20131 employees
Revenue 2024
NOK 679K
+74% vs 2023
EBITDA margin
-1.8%
+94% vs 2023
Equity ratio
-69.4%
Financial strength
Net profit 2024
NOK -36K
+84% vs 2023
| Revenue | NOK 679K | +74% |
| EBITDA | NOK -12K | +94% |
| Net profit | NOK -36K | +84% |
| Total assets | NOK 435K | +48% |
| Equity | NOK -302K | -13% |
| Employees | 1 | — |
Legal name
SIRIS BIOFOTONTERAPI AS
Org number
911943212
Legal form
Aksjeselskap
NACE code
8699 · Other human health activities n.e.c.
Founded
15. mai 2013
Share capital
NOK 30 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Tilby biofotonterapi samt annen virksomhet forbundet med dette, herunder å eie aksjer i andre selskaper.
Address
Galterudbekken 55B, 2614 Lillehammer
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 198 | 232 | 347 | 272 | 311 | 379 | 308 | 418 | 492 | 431 | 389 | 679 |
| Staff expenses | −122 | −116 | −154 | −198 | −163 | −281 | −211 | −200 | −309 | −328 | −216 | −347 |
| EBITDA | 26 | 9 | 75 | −18 | 25 | −10 | −25 | 87 | −35 | −82 | −208 | −12 |
| Depreciation & amort. | −8 | −8 | −8 | −8 | −10 | −15 | −15 | −13 | −6 | −6 | −10 | −23 |
| EBIT | 18 | 1 | 66 | −27 | 14 | −25 | −40 | 74 | −41 | −87 | −218 | −36 |
| Net financials | −8 | 0 | 0 | −0 | 0 | 0 | 0 | −0 | 0 | 0 | −1 | 0 |
| Profit before tax | 10 | 1 | 66 | −27 | 14 | −25 | −40 | 73 | −41 | −87 | −219 | −36 |
| Tax | 0 | −0 | 20 | −3 | −0 | −0 | −0 | 4 | −0 | −0 | −0 | −0 |
| Net profit | 9 | 1 | 47 | −25 | 14 | −25 | −40 | 69 | −41 | −87 | −219 | −36 |
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 86 | 90 | 174 | 168 | 123 | 177 | 138 | 202 | 182 | 81 | 294 | 435 |
| Equity | 39 | 40 | 87 | 62 | 76 | 51 | 11 | 81 | 40 | −48 | −267 | −302 |
| Long-term debt | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 354 | 354 |
| Short-term debt | 47 | 50 | 84 | 106 | 46 | 125 | 127 | 121 | 142 | 129 | 207 | 384 |
| Total debt | 47 | 50 | 87 | 106 | 46 | 125 | 127 | 121 | 142 | 129 | 561 | 738 |
EBITDA margin
-1.8%
This company
15.8%
Market median
-111% vs market
20132024
Equity ratio
-69.4%
This company
38.2%
Market median
-282% vs market
20132024
Return on equity
-3571000.0%
This company
18.4%
Market median
-19407709% vs market
20132024
Net profit margin
-5.3%
This company
8.1%
Market median
-165% vs market
20132024
Asset turnover
1.56×
This company
1.12×
Market median
+39% vs market
20132024
Debt / equity
2.44×
This company
0.62×
Market median
-294% vs market
20132024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-05-10 – 2013-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2018 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of SIRIS BIOFOTONTERAPI AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Siri Kluften | Chairman | 0 companies |